Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M213,141Revenue $M50,912Net Margin (%)17.6Altman Z-Score3.5
Enterprise Value $M229,261EPS $1.3Operating Margin %27.4Piotroski F-Score5
P/E(ttm)23.5Beneish M-Score-2.9Pre-tax Margin (%)23.8Higher ROA y-yN
Price/Book9.910-y EBITDA Growth Rate %--Quick Ratio0.9Cash flow > EarningsY
Price/Sales4.25-y EBITDA Growth Rate %1.2Current Ratio1.2Lower Leverage y-yY
Price/Free Cash Flow18.8y-y EBITDA Growth Rate %-2.5ROA % (ttm)12.1Higher Current Ratio y-yN
Dividend Yield %3.2PEG19.7ROE % (ttm)46.1Less Shares Outstanding y-yY
Payout Ratio %74.0Shares Outstanding M6,816ROIC % (ttm)30.4Gross Margin Increase y-yN

Gurus Latest Trades with RHHBY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RHHBYKen Fisher 2015-12-31 Add0.01%$32.55 - $35.08
($33.69)
$ 31.27-7%Add 0.63%14,630,453
RHHBYKen Fisher 2015-09-30 Add0.02%$31.65 - $36.87
($34.69)
$ 31.27-10%Add 2.30%14,538,602
RHHBYKen Fisher 2015-06-30 Add0.8%$34.38 - $38.46
($36.09)
$ 31.27-13%Add 409.71%14,211,412
RHHBYKen Fisher 2015-03-31 Reduce$32.1 - $36.505
($34.06)
$ 31.27-8%Reduce -1.24%2,788,126
RHHBYKen Fisher 2014-12-31 Add0.07%$34.16 - $37.92
($36.33)
$ 31.27-14%Add 49.26%2,823,025
RHHBYKen Fisher 2014-06-30 Reduce-0.07%$35.42 - $38.07
($36.82)
$ 31.27-15%Reduce -49.71%1,813,443
RHHBYKen Fisher 2014-03-31 Add0.07%$18.14 - $38.17
($29.75)
$ 31.275%Add 99.00%3,606,140
RHHBYKen Fisher 2013-12-31 Reduce$31.96 - $35.24
($34.15)
$ 31.27-8%Reduce -0.26%1,812,112
RHHBYKen Fisher 2013-09-30 Add$30.66 - $33.77
($31.86)
$ 31.27-2%Add 0.28%1,816,868
RHHBYKen Fisher 2013-06-30 Add$28.92 - $32.98
($30.91)
$ 31.271%Add 0.90%1,811,804
RHHBYTweedy Browne 2013-06-30 Sold Out $28.92 - $32.98
($30.91)
$ 31.271%Sold Out0
RHHBYKen Fisher 2013-03-31 Add0.12%$25.62 - $29.3
($27.78)
$ 31.2713%Add 634.57%1,795,722
RHHBYTweedy Browne 2012-12-31 Reduce$23.08 - $25.68
($24.53)
$ 31.2727%Reduce -3.04%120,548
RHHBYKen Fisher 2012-12-31 Reduce$23.08 - $25.68
($24.53)
$ 31.2727%Reduce -14.81%244,460
RHHBYTweedy Browne 2012-09-30 Reduce-0.03%$20.99 - $24.07
($22.5)
$ 31.2739%Reduce -24.31%124,328
RHHBYKen Fisher 2012-09-30 Reduce$20.99 - $24.07
($22.5)
$ 31.2739%Reduce -7.27%286,946
RHHBYVanguard Health Care Fund 2012-06-30 Add2.96%$19.43 - $23.14
($21.18)
$ 31.2748%Add 543.36%8,547,954
RHHBYKen Fisher 2012-06-30 Reduce-0.01%$19.43 - $23.14
($21.18)
$ 31.2748%Reduce -24.26%309,426
RHHBYKen Fisher 2012-03-31 Reduce-1.27%$20.89 - $22.5
($21.78)
$ 31.2744%Reduce -98.02%408,552
RHHBYTweedy Browne 2012-03-31 Reduce-0.04%$20.89 - $22.5
($21.78)
$ 31.2744%Reduce -22.19%164,260
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RHHBY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RHHBY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about RHHBY:

    News about RHHBY:

    Articles On GuruFocus.com
    Invesco European Growth Fund Adds to 7 Stakes Jan 26 2016 
    Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Oct 12 2015 
    Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
    Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 
    UnitedHealth Group Reports Strong Second Quarter Earnings Results Jul 21 2015 
    It’s Not Too Late To Buy Gilead Sciences Jul 17 2015 
    Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
    Roche’s Oncology Drugs Drive Its Revenue Northwards In Q1 Apr 24 2015 
    Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 
    What Are The Intrinsic Factors Contributing To Pfizer’s Stock Movement? Mar 27 2015 

    More From Other Websites
    Roche to Stop Study on Lung Cancer Drug Alecensa Early Feb 11 2016
    Latest developments in cancer research and treatment explored by top global scientists at Tucson... Feb 08 2016
    Roche Holding AG Earnings Analysis: 2015 By the Numbers Feb 05 2016
    ROCHE HOLDING LTD /FI Financials Feb 04 2016
    Pacific Biosciences (PACB) Jumps: Stock Moves Up 24.3% Feb 03 2016
    Roche eyes acquisition of Pacific Biosciences-sources Feb 02 2016
    Roche's Stock May Have Been Down, But The Company's Business Has Strong Outlook Feb 02 2016
    Updated cervical cancer screening guidelines from leading ob-gyn society support expanded use of... Feb 01 2016
    Roche's (RHHBY) Earnings Miss Estimates, Revenues Beat Jan 29 2016
    Roche annual profit disappoints, outlook muted Jan 28 2016
    Roche annual profit disappoints, outlook muted Jan 28 2016
    Roche annual profit disappoints, outlook muted Jan 28 2016
    European shares fall, hit by weak earnings and banks Jan 28 2016
    European shares fall, hit by weak earnings and banks Jan 28 2016
    [$$] Roche Profit Dented by Strong Swiss Franc Jan 28 2016
    European shares down in choppy trade led by Roche; oils up Jan 28 2016
    Roche earnings fall short of forecasts Jan 28 2016
    Roche Falls After Full-Year Profit Misses Analyst Estimates Jan 28 2016
    Coverage initiated on Roche Hldg by Piper Jaffray Jan 22 2016
    Roche/AbbVie's Leukemia Drug Gets Breakthrough Status Jan 21 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    Steve.dunfield@google
    ReplySteve.dunfield@google - 1 year ago
    Adjust for split?
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK